Halozyme Therapeutics (HALO) Competitors

Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Do analysts prefer BIIB or HALO?

Biogen presently has a consensus price target of $180.69, indicating a potential upside of 24.35%. Halozyme Therapeutics has a consensus price target of $73.00, indicating a potential upside of 9.53%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	19 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.32
Halozyme Therapeutics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Which has stronger valuation & earnings, BIIB or HALO?

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	2.20	$1.63B	$10.46	13.89
Halozyme Therapeutics	$1.02B	7.68	$444.09M	$4.37	15.25

Do institutionals and insiders have more ownership in BIIB or HALO?

87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 2.9% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media favor BIIB or HALO?

In the previous week, Biogen had 11 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 39 mentions for Biogen and 28 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.78 beat Biogen's score of 0.54 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	13 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, BIIB or HALO?

Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Is BIIB or HALO more profitable?

Halozyme Therapeutics has a net margin of 47.28% compared to Biogen's net margin of 15.31%. Halozyme Therapeutics' return on equity of 150.85% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.31%	13.85%	8.32%
Halozyme Therapeutics	47.28%	150.85%	29.19%

Summary

Halozyme Therapeutics beats Biogen on 10 of the 16 factors compared between the two stocks.